{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:40:32Z","timestamp":1786653632970,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The goal of this research is to investigate the clinical characteristics and prognosis of men with metastatic breast cancer (mMBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis of the data of 28 patients was conducted. Kaplan\u2013Meier and Cox regression analyses were used to assess overall survival (OS) and prognostic variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At the time of diagnosis, the median age was 57 years (range 26\u201386). The most prevalent pathological subtype was invasive ductal carcinoma (92.6%). HER2 positivity was 21.6% in patients, with estrogen and progesterone receptor positivity at 96.4% and 71.4%, respectively. Bone-75%, lung-39.3%, brain-21.4%, and adrenal gland-10.7% were the most prevalent metastatic sites. Trastuzumab-based chemotherapy was given to six patients. During the study period, 14 patients (or half) died. All patients had a median OS of 42.6 months (range: 21.6\u201363.7). The OS rates after 1, 3, and 5 years were 95.7%, 54.2%, and 36.6%, respectively. The number of metastatic locations (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.045), brain metastasis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.033), and a history of regular alcohol intake (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008) were all shown to be statistically significant factors affecting OS in univariate analysis. However, multivariate analysis did not support the findings. In addition, we discovered that trastuzumab-based therapy and de-novo metastatic disease had no effect on OS for mMBC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The data on mMBC is restricted because of its rarity. The prognosis of mMBC was shown to be poor in this investigation. Despite the small number of patients, we discovered that in univariate analysis, having brain metastases, the number of metastatic locations, and a history of alcohol intake may be prognostic factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1829_22","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T15:01:44Z","timestamp":1711810904000},"page":"98-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of the patients with metastatic male breast cancer"],"prefix":"10.4103","volume":"20","author":[{"given":"Izzet","family":"Dogan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nijat","family":"Khanmammadov","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selnur","family":"Ozkurt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Aydiner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Saip","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"key":"R1-20260507","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260507","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-018-4921-9","article-title":"Male breast cancer:A disease distinct from female breast cancer","volume":"173","author":"Gucalp","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R3-20260507","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1016\/j.clbc.2018.06.013","article-title":"Male breast cancer:An updated surveillance, epidemiology, and end results data analysis","volume":"18","author":"Liu","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"R4-20260507","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdx651","article-title":"Characterization of male breast cancer:Results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"R5-20260507","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of male breast cancer:ASCO guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"key":"R6-20260507","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/B:BREA.0000019953.92921.7e","article-title":"Her-2\/neu gene amplification and protein expression in primary male breast cancer","volume":"84","author":"Rudlowski","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"R7-20260507","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14740\/wjon1418","article-title":"Management of male breast cancer:The journey so far and future directions","volume":"12","author":"Sabih","year":"2021","journal-title":"World J Oncol"},{"key":"R8-20260507","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2009.23.8162","article-title":"Male breast cancer:A population-based comparison with female breast cancer","volume":"28","author":"Anderson","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-20260507","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000365953","article-title":"Metastatic male breast cancer:A retrospective cohort analysis","volume":"9","author":"Foerster","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"R10-20260507","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13046-015-0143-8","article-title":"Efficacy of chemotherapy in metastatic male breast cancer patients:A retrospective study","volume":"34","author":"Di Lauro","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"R11-20260507","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1055-9965.EPI-07-2897","article-title":"Effect of prediagnostic alcohol consumption on survival after breast cancer in young women","volume":"17","author":"Reding","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R12-20260507","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2010.29.2730","article-title":"Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer:The life after cancer epidemiology study","volume":"28","author":"Kwan","year":"2010","journal-title":"J Clin Oncol"},{"key":"R13-20260507","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-020-06052-z","article-title":"The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis:A population-based study","volume":"187","author":"Leone","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"R14-20260507","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","article-title":"Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis","volume":"161","author":"Leone","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"R15-20260507","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.clbc.2017.07.005","article-title":"Treatment outcomes and prognostic factors in male patients with stage IV breast cancer:A population-based study","volume":"18","author":"Chen","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"R16-20260507","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/s10434-021-10729-0","article-title":"Benefits of trimodality therapy compared with systemic therapy alone in male patients with stage IV breast cancer","volume":"29","author":"Stahl","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R17-20260507","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1245\/s10434-020-09244-5","article-title":"Benefits of surgical treatment of stage IV breast cancer for patients with known hormone receptor and HER2 status","volume":"28","author":"Stahl","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R18-20260507","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12282-008-0060-1","article-title":"A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment","volume":"16","author":"Hayashi","year":"2009","journal-title":"Breast Cancer"},{"key":"R19-20260507","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.breast.2006.12.010","article-title":"Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer","volume":"16","author":"Carmona-Bayonas","year":"2007","journal-title":"Breast"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1829_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:13Z","timestamp":1786650013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1829_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1829_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"2022-08-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}